Poker player

Donavan Chu

Hong Kong SAR China

Donavan Chu is a professional poker player from Hong Kong who competes in major Asian poker tours. He has recorded cashes at APT Taipei 2026, APT Manila 2025, and USOP Hai Phong 2024, with total live earnings over $21,000. Chu is known for his consistent deep runs in Main Events across the region.

Career earnings: $ 64,1859 views

Player Overview

Donavan Chu is a Hong Kong-based professional poker player active in the Asian tournament circuit. His recorded results span events from the Asian Poker Tour (APT) and the U Series of Poker (USOP), with a total of three WSOP.com-recorded cashes and live earnings of $21,685 as of 2026.

Tournament Highlights

Chu's most notable finishes include a deep run at the APT Taipei 2026 Main Event (Event #54), where he placed 51st out of 1,300 entrants, earning NT$285,500 (approximately $9,100). At the APT Manila Classic 2025 (Event #18), he finished 18th out of 673 players for ₱425,000 (around $7,300). His third recorded cash came at the USOP Hai Phong Grand Finale 2024 Championship Event (Event #26), placing 89th out of 1,334 entries for ₫127,030,000 (about $5,200).

Notable Results

Series/EventDateRankEntriesEarnings (Local)Earnings (USD approx.)
APT Taipei 2026 (Event #54) – Main EventMay 202651st1,300NT$285,500$9,100
APT Manila Classic 2025 (Event #18) – Main EventFeb 202518th673₱425,000$7,300
USOP Hai Phong Grand Finale 2024 – Championship EventDec 202489th1,334₫127,030,000$5,200

Career Summary

Based on available data, Donavan Chu has accumulated $21,685 in live tournament earnings across three known cashes. His best single cash stands at $9,120 from the APT Taipei 2026 Main Event. He has also participated in several other events, including the APT Taipei 2026 Main Event (2,354 entries) and APT Manila Classic 2025 (1,202 entries), indicating a consistent presence in Asia's largest poker gatherings. While his playing style is not publicly documented, his ability to make multiple final tables in Main Event fields suggests a strategic and patient approach.

Comments (0)

|

Sign in to join the discussion

Related